Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).
Al-Sawaf O, Bazeos A, Robrecht S, Bahlo J, Gower C, Fink AM, Tresckow J, Cramer P, Langerbeins P, Kutsch N, Humphrey K, Fingerle-Rowson G, Stilgenbauer S, Wendtner CM, Fischer K, Eichhorst B, Hallek M, Goede V. Al-Sawaf O, et al. Among authors: humphrey k. Am J Hematol. 2019 Sep;94(9):1002-1006. doi: 10.1002/ajh.25561. Epub 2019 Jul 8. Am J Hematol. 2019. PMID: 31222797 Free article. Clinical Trial.
Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in.
Goede V, Fischer K, Busch R, Jaeger U, Dilhuydy MS, Wickham N, De Guibert S, Ritgen M, Langerak AW, Bieska G, Engelke A, Humphrey K, Wenger M, Hallek M. Goede V, et al. Among authors: humphrey k. Leukemia. 2013 Apr;27(5):1172-4. doi: 10.1038/leu.2012.252. Epub 2012 Aug 31. Leukemia. 2013. PMID: 22936013 Clinical Trial. No abstract available.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Goede V, et al. Among authors: humphrey k. N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8. N Engl J Med. 2014. PMID: 24401022 Free article. Clinical Trial.
Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab.
Freeman CL, Dixon M, Houghton R, Kreuzer KA, Fingerle-Rowson G, Herling M, Humphrey K, Böttcher S, de Costa CS, Iglesias V, Stilgenbauer S, Gribben J, Hallek M, Goede V. Freeman CL, et al. Among authors: humphrey k. Leukemia. 2016 Aug;30(8):1763-6. doi: 10.1038/leu.2016.41. Epub 2016 Mar 4. Leukemia. 2016. PMID: 26979130 Free PMC article. No abstract available.
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJM, Böttcher S, Ritgen M, Goede V, Mobasher M, Hallek M. Fischer K, et al. Among authors: humphrey k. Blood. 2017 May 11;129(19):2702-2705. doi: 10.1182/blood-2017-01-761973. Epub 2017 Mar 21. Blood. 2017. PMID: 28325865 Free PMC article. Clinical Trial. No abstract available.
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. Seymour JF, et al. Among authors: humphrey k. N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976. N Engl J Med. 2018. PMID: 29562156 Free article. Clinical Trial.
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, Steurer M, Trněný M, Mulligan SP, Mey UJM, Trunzer K, Fingerle-Rowson G, Humphrey K, Stilgenbauer S, Böttcher S, Brüggemann M, Hallek M, Kneba M, van Dongen JJM. Langerak AW, et al. Among authors: humphrey k. Blood. 2019 Jan 31;133(5):494-497. doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19. Blood. 2019. PMID: 30455380 Free PMC article. Clinical Trial.
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. Kater AP, et al. Among authors: humphrey k. J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. Epub 2018 Dec 3. J Clin Oncol. 2019. PMID: 30523712 Free article. Clinical Trial.
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ. Flinn IW, et al. Among authors: humphrey k. Blood. 2019 Jun 27;133(26):2765-2775. doi: 10.1182/blood-2019-01-896290. Epub 2019 Mar 12. Blood. 2019. PMID: 30862645 Free PMC article. Clinical Trial.
141 results